Pharmagene Discovery Services — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Pharmagene Discovery Services is a long-established, specialized CRO operating from Cambridge, UK, with a core focus on human tissue-based translational research. The company's business model is built on providing integrated services that combine access to a curated human tissue bank, scientific expertise in assay development (particularly immunohistochemistry), and advanced translational models to support drug development from target validation through clinical stages. Its key offerings include GLP-compliant Tissue Cross-Reactivity (TCR) studies for biotherapeutic safety and clinical sample processing, positioning it as a partner for de-risking development and reducing clinical attrition. As a private, services-based company, it generates revenue through contracted research projects.

Small MoleculesDrug Discovery

Technology Platform

Integrated platform centered on a curated bank of high-quality human biospecimens, combined with expertise in tissue-based assay development (particularly immunohistochemistry), advanced translational cellular models, and GLP/GCLP-certified laboratory operations.

Opportunities

Growing demand for human-relevant translational data to de-risk expensive clinical trials, especially for complex biologics, creates a strong market tailwind.

Expansion of its tissue bank and model systems into emerging disease areas or advanced modalities (e.g., cell therapies) could open new service lines.

Strategic partnerships with larger, full-service CROs could provide a steady stream of client referrals.

Risk Factors

Regulatory changes that reduce requirements for tissue cross-reactivity studies could impact a core service line.

Intense competition from both large CROs and niche specialists threatens market share.

Operational reliance on a consistent supply of ethically sourced, high-quality human tissues presents a potential bottleneck and reputational risk.

Competitive Landscape

Pharmagene competes in a fragmented CRO market. It faces competition from large, full-service global CROs (e.g., LabCorp, IQVIA, Charles River) that offer similar translational services, as well as from other specialized, tissue-focused research providers and academic core facilities. Its differentiation lies in its deep, long-standing expertise specifically in human tissue IHC and TCR studies, combined with direct access to its own tissue bank.

More companies in United Kingdom →